Showing 421 - 440 results of 42,077 for search '(( 5 we decrease ) OR ( 50 ((((nn decrease) OR (teer decrease))) OR (a decrease)) ))', query time: 0.98s Refine Results
  1. 421
  2. 422
  3. 423
  4. 424
  5. 425
  6. 426
  7. 427
  8. 428

    DataSheet2_WNT5A Interacts With FZD5 and LRP5 to Regulate Proliferation and Self-Renewal of Endometrial Mesenchymal Stem-Like Cells.docx by Tianqi Li (1335987)

    Published 2022
    “…Among the various receptors that have been reported to interact with WNT5A, we found FZD5 abundantly expressed by eMSC when compared to unfractionated stromal cells. …”
  9. 429

    DataSheet1_WNT5A Interacts With FZD5 and LRP5 to Regulate Proliferation and Self-Renewal of Endometrial Mesenchymal Stem-Like Cells.docx by Tianqi Li (1335987)

    Published 2022
    “…Among the various receptors that have been reported to interact with WNT5A, we found FZD5 abundantly expressed by eMSC when compared to unfractionated stromal cells. …”
  10. 430

    Hsa_circ_0017639 regulates cisplatin resistance and tumor growth via acting as a miR-1296-5p molecular sponge and modulating sine oculis homeobox 1 expression in non-small cell lun... by Feiyun Chang (12243382)

    Published 2022
    “…The regulation mechanism of circ_0017639 was demonstrated by a dual-luciferase reporter assay. We observed higher levels of circ_0017639 in DDP-resistant NSCLC samples and cells. …”
  11. 431
  12. 432
  13. 433
  14. 434

    DataSheet5_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

    Published 2021
    “…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
  15. 435
  16. 436
  17. 437
  18. 438
  19. 439
  20. 440